Insight Molecular Diagnostics Inc.
IMDXHealthcareNASDAQDiagnostics & Research · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the healthcare sector, Insight Molecular Diagnostics Inc. (IMDX) is listed under Diagnostics & Research. The $139.7M market capitalization puts IMDX squarely in micro-cap range for its industry. operates as a precision diagnostics company in the United States and internationally.
Market Cap
$139.7M
Beta
1.80
P/E (TTM)
—
P/E (Fwd)
-5.34
EPS (TTM)
$-1.52
EPS (Fwd)
$-0.80
ROE
—
ROA
-57.8%
Cash
$17.8M
Total Debt
$2.6M
Free CF
-$18.8M
52W Change
54.7%
Annual Financials
Cash vs Debt
Where IMDX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, IMDX finished 19.15% below its 150-day moving average ($4.96) and 23.91% below its 200-day moving average ($5.27). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMDX overbought or oversold?
At the September 3, 2026 close, IMDX's RSI(14) was 58.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Insight Molecular Diagnostics Inc. holds $17.8M in cash against $2.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$18.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $958K (2022) to $4.1M (2025), reflecting a 323% increase over the period.
Insight Molecular Diagnostics Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, IMDX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing IMDX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.